AstraZeneca's Evusheld Revenue Stream To Dry Up Soon
As FDA Withdraws Authorization Of COVID-19 Therapy
The revenue boost Evusheld has given AstraZeneca over the past year will grind to a halt now that the FDA, as expected, has pulled approval for the antibody combo on the grounds it is ineffective against most SARS-CoV-2 variants circulating in the US.
You may also be interested in...
UK’s NICE Says No To AstraZeneca’s Evusheld Amid ‘Rapidly Changing’ COVID-19 landscape
NICE says that limitations in the evidence for Evusheld make it difficult to produce a reliable cost-effectiveness estimate.
Disappointment & Surprise But Not Giving Up: Companies Respond To English Funding Rejection For COVID-19 Treatments
MSD, Gilead, GSK, AstraZeneca and Roche told the Pink Sheet what they thought of draft guidance that the health technology assessment institute, NICE, published today, recommending against routine commissioning for five COVID-19 treatments.
AstraZeneca To Remain In Vaccines For The Long Haul
The highs and lows experienced with its COVID-19 vaccine Vaxzevria have not deterred the UK giant from keeping a presence in the field and CEO Pascal Soriot told Scrip that the path could mirror the decade-long journey AstraZeneca had in oncology before it achieved sustained success.